Literature DB >> 7972021

Ribozyme-mediated reversal of the multidrug-resistant phenotype.

K J Scanlon1, H Ishida, M Kashani-Sabet.   

Abstract

This study examined the effects of suppressing c-fos oncogene expression on multidrug resistance (MDR). A2780S human ovarian carcinoma cells with resistance to actinomycin D were isolated and the resultant A2780AD cells exhibited the MDR phenotype. A hammerhead ribozyme designed to cleave fos RNA cloned into the pMAMneo plasmid was transfected into A2780AD cells. Induction of the ribozyme resulted in decreased expression of c-fos, as well as that of the MDR gene (mdr-1), c-jun, and mutant p53. The transformants displayed altered morphology and restored sensitivity to chemotherapeutic agents comprising the MDR phenotype. An anti-mdr ribozyme separately expressed in A2780AD cells efficiently degraded mdr-1 mRNA. However, reversal of the MDR phenotype by the anti-mdr ribozyme occurred one-fourth as rapidly as that induced by the anti-fos ribozyme. These results reinforce the central role played by c-fos in drug resistance through its participation in signal transduction pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972021      PMCID: PMC45179          DOI: 10.1073/pnas.91.23.11123

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

Review 2.  Nuclear proto-oncogenes fos and jun.

Authors:  L J Ransone; I M Verma
Journal:  Annu Rev Cell Biol       Date:  1990

Review 3.  Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1.

Authors:  D Bohmann; T J Bos; A Admon; T Nishimura; P K Vogt; R Tjian
Journal:  Science       Date:  1987-12-04       Impact factor: 47.728

Review 4.  The biochemistry of P-glycoprotein-mediated multidrug resistance.

Authors:  J A Endicott; V Ling
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

5.  Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.

Authors:  M Kashani-Sabet; W Wang; K J Scanlon
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

6.  Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways.

Authors:  L D Kerr; J T Holt; L M Matrisian
Journal:  Science       Date:  1988-12-09       Impact factor: 47.728

7.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Authors:  K J Scanlon; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

8.  Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters.

Authors:  A Schönthal; P Herrlich; H J Rahmsdorf; H Ponta
Journal:  Cell       Date:  1988-07-29       Impact factor: 41.582

9.  Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene.

Authors:  K Ueda; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

10.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.

Authors:  D W Shen; A Fojo; J E Chin; I B Roninson; N Richert; I Pastan; M M Gottesman
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

View more
  15 in total

1.  A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency.

Authors:  D A Samarsky; G Ferbeyre; E Bertrand; R H Singer; R Cedergren; M J Fournier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Efficient and specific ribozyme-mediated reduction of bovine alpha-lactalbumin expression in double transgenic mice.

Authors:  P J L'Huillier; S Soulier; M G Stinnakre; L Lepourry; S R Davis; J C Mercier; J L Vilotte
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  The role of oncogenes in drug resistance.

Authors:  D Yu
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.

Authors:  M Sioud
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

5.  Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.

Authors:  Y Ohta; H Kijima; T Ohkawa; M Kashani-Sabet; K J Scanlon
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

6.  Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.

Authors:  S J Collis; A Tighe; S D Scott; S A Roberts; J H Hendry; G P Margison
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

7.  mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.

Authors:  C Daly; S Coyle; S McBride; L O'Driscoll; N Daly; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

8.  Ribozyme as an approach for growth suppression of human pancreatic cancer.

Authors:  H Kijima; K J Scanlon
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

Review 9.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

10.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.